Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | FT536 |
Trade Name | |
Synonyms | FT-536|FT 536 |
Drug Descriptions |
FT536 comprises iPSC-derived natural killer cells with deletion of CD38 and expressing an IL-15-IL15 receptor fusion and non-cleavable CD16 that have been engineered to express a chimeric antigen receptor (CAR) targeting the alpha3 domain of MICA and MICB, which potentially inhibits growth of MICA/B-expressing tumors (Cancer Res (2021) 81 (13_Supplement): 1591). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
FT536 | FT536 | 0 | 1 |